BMS - Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

BMS faces shareholder opposition to $74bn Celgene acquisition

BMS
BMS expects its merger with Celgene to create a premier biopharma company. Credit: Rept0n1x.